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Abstract: Our aim is to describe the study recruitment and baseline characteristics of the 
Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability 
(FINGER) study population. Potential study participants (age 60–77 years, the dementia 
risk score ≥6) were identified from previous population-based survey cohorts and invited to 
the screening visit. To be eligible, cognitive performance measured at the screening visit 
had to be at the mean level or slightly lower than expected for age. Of those invited  
(n = 5496), 48% (n = 2654) attended the screening visit, and finally 1260 eligible 
participants were randomized to the intervention and control groups (1:1). The screening 
visit non-attendees were slightly older, less educated, and had more vascular risk factors 
and diseases present. The mean (SD) age of the randomized participants was 69.4 (4.7) 
years, Mini-Mental State Examination 26.7 (2.0) points, systolic blood pressure  
140.1 (16.2) mmHg, total serum cholesterol 5.2 (1.0) mmol/L for, and fasting glucose  
6.1 (0.9) mmol/L for, with no difference between intervention and control groups. Several 
modifiable risk factors were present at baseline indicating an opportunity for the 
intervention. The FINGER study will provide important information on the effect of 
lifestyle intervention to prevent cognitive impairment among at risk persons. 
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1. Introduction 
With the aging population, it has been projected that the number of persons with cognitive 
impairment and dementia will increase rapidly in the coming years [1]. Longitudinal population-based 
studies have identified many potentially modifiable vascular, metabolic, and life-style related risk 
factors for dementia and Alzheimer’s disease (AD) [2]. 
Interventions on modifiable risk factors may prevent/postpone dementia onset, but the 
pharmacological and non-pharmacological intervention studies conducted so far have had somewhat 
disappointing results as pointed out in a report by the National Institutes of Health [3]. There are 
several reasons for this. Previous trials have mostly used a single agent intervention and they have 
been conducted in older and/or already cognitively impaired populations, which may partly explain the 
modest results. Many of these trials were planned for other outcomes and cognitive outcomes were 
secondary. There are however some positive signs that antihypertensive drug treatment [4], vitamin B 
supplementation [5], physical activity [6] and cognitive training [7] may be beneficial, at least in 
certain population groups. Given the multifactorial nature of dementia/AD, and the long prodromal 
period, it has been proposed that the optimal feasible clinical trial should be a multidomain 
intervention targeting an at-risk population [3]. Such multidomain lifestyle interventions have 
demonstrated dramatic benefits in the development of type 2 diabetes in high-risk individuals [8]. 
To interpret the results of the intervention studies and to use the results in developing intervention 
programs, it is important to understand who participates in these trials, and to what extent the results 
may be generalizable. Little is known about the determinants of participation in clinical trials among 
older people, as studies are often conducted at memory clinic settings or among volunteers recruited 
through advertisements, etc. In one cognitive training trial, participants were younger, more likely to 
be female, and had higher education than the general population of the same age-range [9]. Often these 
demographic data are the only data available for comparison. In some previous observational studies it 
has been reported that the non-participants had lower cognitive test performance [10] and higher 
prevalence of dementia [11]. There are few health promotion and physical activity trials among older 
adults, however not focusing on AD or cognition, with varying reports on non-participation: the 
participants have reported more health problems [12] than the non-participants in one study, but better 
health in another [13]. One study reported that while those non-participants who refused to participate 
were healthier, those who could not be reached were less healthy than the participants [14]. 
We have initiated the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and 
Disability (FINGER) [15] to investigate whether a multidomain intervention could prevent cognitive 
decline and eventually dementia. It is a 2-year randomized controlled trial (RCT) targeting several 
known risk factors simultaneously through an intervention consisting of nutritional guidance, exercise 
training, cognitive training, and intensive monitoring of vascular risk factors. The participants were 
recruited from earlier population-based cardiovascular disease and type 2 diabetes (non-intervention) 
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surveys, which gives us unique background information on both participants and those that did not 
participate. This is rarely available in clinical trials. The aim of this report is two-fold: first we will 
describe the demographic, medical and lifestyle characteristics of screening visit attendees and non-
attendees. Second, we will describe the recruitment process and baseline characteristics and cognitive 
assessments of the study participants in the intervention and control groups. 
2. Experimental Section 
The protocol of the FINGER study (ClinicalTrials.gov identifier: NCT01041989) has been 
described earlier [15]. In brief, the FINGER study is an ongoing multi-centre randomized controlled 
trial. The 2-year multidomain intervention consists of nutritional guidance; exercise; cognitive training 
and social activity; and management of metabolic and vascular risk factors. Persons in the control 
group receive regular health advice. The primary outcome is cognitive performance measured with the 
modified Neuropsychological Test Battery (mNTB). Main secondary outcomes are: dementia (after 
extended follow-up), disability, vascular risk factors and outcomes, depressive symptoms, quality of 
life, and neuroimaging measures. The intensive intervention was completed in 2014, and the 
participants are followed-up for additional five years. The FINGER study has been approved by the 
Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. The participants gave 
written informed consent at the time of both the screening and baseline visits. 
2.1. Recruitment 
The participants were recruited from persons who had earlier participated in population-based  
non-communicable disease risk factor surveys: the National FINRISK study [16] in 1972, 1977, 1982, 
1987, 1992, 1997, 2002 or 2007, or the Finnish type 2 diabetes prevention program’s population 
survey [17] in 2004 or 2007. These independent cross-sectional surveys were conducted for health 
surveillance purposes to monitor chronic disease risk factor levels in the population. The participation 
rates of these surveys were good, ranging from 70% to above 96% in the birth cohort that was the 
target of the FINGER study [16,18]. The recruitment of participants was started from the most recent 
survey, and moved on to earlier surveys when all eligible persons of the most recent survey had  
been invited. 
To be invited, the person had to be aged 60–77 years (born between 1 January 1932 and  
31 December 1949) at the beginning of the study, and have Cardiovascular Risk Factors, Aging and 
Incidence of Dementia (CAIDE) Dementia Risk Score [19] of 6 points or higher, and be alive when 
the sample was drawn in May 2009. The score includes easily measurable variables (age, sex, 
education, hypertension, hypercholesterolemia, obesity and physical inactivity) that are associated with 
the risk of dementia. The 6 points cut-off is relatively low but indicates a presence of some modifiable 
risk factors. The majority (84%) of our source population met this criterion, excluding only those with 
very low risk of dementia. At the screening visit participants’ cognition was assessed with The 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological  
battery [20]. To be included in the FINGER, the participants had to fulfil at least one of the following 
criteria: (1) Word List Learning task (10 words × 3) ≤19 words; or (2) Word List Recall ≤75%; or (3) 
Mini Mental State Examination (MMSE) ≤26/30 points. This criteria selects persons with cognitive 
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performance at the mean level or slightly lower than expected for age according to Finnish population 
norms (inclusion cut-off z-scores −0.5, −0.2 and −0.9 respectively) [21]. Theoretical formation of this 
at-risk population is presented in Figure 1. Exclusion criteria were conditions affecting engagement in 
the intervention (especially the exercise component): present malignant diseases, major depression, 
dementia/substantial cognitive decline according to clinical interview, MMSE < 20, symptomatic 
cardiovascular disease, re-vascularisation within one year, severe loss of vision, hearing or 
communicative ability, conditions preventing co-operation as judged by the local study physician, as 
well as coincident participation in any other intervention trial. 
Figure 1. FINGER inclusion criteria and target population. 
 
Screening began in September 2009 in the five original study areas in Finland (in and around the 
cities of Helsinki, Kuopio, Oulu, Seinäjoki, Vantaa), and a sixth area (Turku) was added in April 2010 
to ensure sufficient recruitment in a reasonable time frame. Screening was completed in December 
2011 when the intended recruitment target (n = 1200) was achieved. 
After completing the baseline measurements randomization was performed in blocks of four 
persons (two persons randomly allocated to each group) at each site by the study nurse running a 
computer program. If spouses participated in the trial, the randomization status of the latter recruited 
spouse was manually changed to match the randomization of the first recruited spouse. 
2.2. Measurements 
The baseline study visit comprised of a detailed medical history and physical examination by 
trained study physicians, and measurements of height (without shoes), weight (in light indoor 
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clothing), waist (midway between the lowest rib and iliac crest) and hip (at the point yielding the 
maximum circumference over the buttocks) circumference in a standing position, and systolic and 
diastolic blood pressure (two measurements using a validated automatic device (Microlife WatchBP 
Office) in a sitting position, using the right arm, after 10 min of rest) by trained study nurses. Mean 
value of two blood pressure measurements was used. A fasting venous blood sample was taken from 
all participants, and a 2 h oral glucose tolerance test with a 75 g glucose load was done in the 
participants without history of diabetes. Fluoride citrate tubes were used for glucose samples. The 
separated serum and plasma samples were frozen immediately and mailed monthly to the laboratory of 
the National Institute for Health and Welfare. Total serum cholesterol and plasma glucose 
concentrations were determined enzymatically using commercial reagents from Abbott Laboratories 
on a clinical chemistry analyzer, Architect c8000 (Abbott Laboratories, Abbott Park, IL, USA). The 
participants filled structured questionnaires including questions of sociodemographic factors, health 
status, lifestyles, mood and quality of life. The Short Physical Performance Battery [22] was 
administered by trained physiotherapists. 
A thorough cognitive assessment using a set of standard neuropsychological tests (an extended and 
adapted version of the NTB [23]) was administered by trained study psychologists. The primary 
outcome measure is the total composite mNTB score including 14 tests that form three different 
cognitive domains. The memory domain included Visual Paired Associates immediate (score range, 
018) and delayed (score range, 0–6); Logical Memory immediate (score range, 0–25) and delayed 
(score range, 0–25) of the Wechsler Memory Scale-Revised (WMS-R) [24]; and Word List Learning 
(score range, 0–30) and Delayed Recall (score range, 0–10) of the CERAD test battery [20]. The 
executive function domain included Category Fluency Test [20], Digit Span [24], Concept Shifting 
Test [25] (condition C), Trail Making Test [26] (shifting score B-A), and a shortened 40-stimulus 
version of the original Stroop test [27] (interference score 3–2). The processing speed domain included 
Letter Digit Substitution Test [28], Concept Shifting Test (condition A), and Stroop test (condition 2). 
All baseline information was collected before randomization. 
In addition to the measurements carried out during the screening and baseline visits, we have 
background information on vascular risk factors and lifestyles available from the earlier background 
surveys. Data on health status were also collected through computerized register linkage to three 
nationwide health registers: the Hospital Discharge Register, the National Social Insurance 
Institution’s Drug Reimbursement Registry, and the Causes of Death registry using the national 
personal identification number. Data on all patients discharged from all hospitals in Finland have been 
recorded in a computerized Hospital Discharge Register since 1968. The diagnoses for hospitalizations 
have been coded according to the International Classification of Diseases (ICD) version 8 during 1968 
to 1986, version 9 during 1987 to 1995, and version 10 since 1996. We used data on hospitalisations 
before the onset of study for myocardial infarction (ICD 8 and 9 diagnoses 410 and ICD-10 diagnoses 
I21–I22), stroke (ICD 8 diagnoses 430, 431 (except 43101, 43191) 433, 434, 436, ICD 9 diagnoses 
430, 431, 4330A, 4331A, 4339A, 4340A, 4341A, 4349A, 436 and ICD 10 diagnoses I60–I64 (not 
I636)), cancer (ICD 8 and 9 diagnoses 140–172, 174–208 and ICD 10 diagnoses C00–C43, C45–C97), 
diabetes (ICD 8 and 9 diagnoses 250 and ICD 10 diagnoses E10–E14), and dementia (ICD 8 diagnosis 
290 ICD 9 diagnoses 290, 3310, 4378A and ICD 10 diagnoses F00, F01, F02, F03, G30). In the 
register the diagnoses are assigned by the physician treating the patient. The Social Insurance 
Int. J. Environ. Res. Public Health 2014, 11 9351 
 
 
Institution’s register (reimbursement of pharmaceutical expenses) was used for diabetes (purchases of 
drugs in Anatomical Therapeutic Chemical (ATC) category A10 or with the Institution’s special 
reimbursement code for diabetes) and dementia (purchases of drugs in ATC category N06D or with 
special reimbursement code for dementia). Currently the data from all of these registers is available 
until end of 2011. 
2.3. Statistical Analyses 
The differences between screening visit attendees and non-attendees, between randomized and  
not-randomized participants, and between intervention and control groups were analysed using chi 
square-test and t-test as appropriate. The level of significance was 5% in all analyses. 
3. Results and Discussion 
3.1. Characteristics of the Persons invited to the FINGER Study 
A total of 5496 persons were invited and 2654 (48% of those invited) attended the screening visit. 
The screening attendance rates between study sites varied from 43% to 57%. Compared with the 
attendees, those who did not attend the screening visit were older, and based on the data from the 
earlier studies they had participated in, they were more likely to be less educated, and have more 
vascular and lifestyle risk factors (Table 1). The screening visit non-attendees also had more vascular 
diseases, diabetes, cancer and dementia as identified through the registries. Mortality between 22 May 
2009 when the study population was identified and the 31 December 2011 (data currently available 
through registers) was higher among those who did not attend the screening visit. Therefore, it is likely 
that many non-responding persons would have been excluded based on our exclusion criteria, had they 
attended the screening visit. 
Table 1. Background characteristics from earlier surveys and health registries of the 
persons who were invited to attend the FINGER study screening visit (mean (SD) or %). 
Characteristic 
All Invited 
n = 5496 
Screened 
n = 2654 
Screening Visit 
Non-Attendees 
n = 2842 
p-Value * 
Age at the beginning of the study (07.09.2009) 68.1 (5.0) 67.8 (4.8) 68.3 (5.2) 0.002 
Sex (% men/women) 50.3/49.7 48.8/51.2 51.7/48.3 0.037 
Study site:     
 Helsinki (n, %) 743 389 (52.3%) 354 (47.6%) <0.001 
 Kuopio (n, %) 1444 625 (43.3%) 819 (56.7%)  
 Oulu (n, %) 420 240 (57.1%) 180 (42.9%)  
 Seinäjoki (n, %) 587 326 (55.5%) 261 (44.5%)  
 Turku (n, %) 1400 656 (46.9%) 744 (53.1%)  
 Vantaa (n, %) 902 418 (46.3%) 484 (53.7%)  
Demographic and vascular risk factors from the earlier non-intervention survey  
Time between earlier survey and invitation (years) 14.3 (10.0) 12.6 (9.7) 15.9 (10.1) <0.001 
Education (years) 10.4 (3.6) 10.7 (3.8) 10.0 (3.5) <0.001 
Systolic blood pressure (mmHg) 143 (18.9) 142 (18.7) 144 (19.1) <0.001 
Total cholesterol (mmol/L) 5.9 (1.1) 5.8 (1.1) 6.0 (1.1) <0.001 
Body mass index (kg/m2) 27.7 (4.6) 27.7 (4.5) 27.7 (4.7) 0.575 
Physical activity at least 2 times/ week (%) 49.9% 52.4 47.5 <0.001 
Dementia risk score (points) 8.4 (1.8) 8.1 (1.7) 8.6 (1.8) <0.001 
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Table 1. Cont. 
Characteristic 
All Invited 
n = 5496 
Screened 
n = 2654 
Screening Visit 
Non-Attendees 
n = 2842 
p-Value * 
History of diseases from registers    
Myocardial infarction (%) 4.1 3.5 4.6 0.032 
Stroke (%) 4.5  3.0 5.8 <0.001 
Diabetes (%) 11.0 8.9 12.9 <0.001 
Cancer (%) 8.7 7.0 10.3 <0.001 
Dementia (%) 1.1 0.3 2.0 <0.001 
Mortality between May 2009 and 31 Dec 2011 (%) 3.2 0.8 5.4 <0.001 
* The p value refers to difference between screening visit attendees and non-attendees. 
Figure 2. Formation of the study population. 
 
Nearly half of the persons who attended the screening visit fulfilled the cognition criteria for 
inclusion (Figure 2). The majority of persons who were not included based on their cognitive 
performance had too high scores, and only seven persons were not included because of too low MMSE 
score. A total of 142 persons were excluded due to other reasons (too ill including persons suspected to 
have significant cognitive impairment, participation in another ongoing intervention trial). 
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Additionally 144 persons dropped out after the screening visit but before randomization. This left us 
with 1260 participants randomized into an intensive multidomain intervention group (intervention,  
n = 631) and a regular health advice group (control, n = 629). 
3.2. Randomized vs. not Randomized Persons 
The persons who attended the screening visit but who were not randomized were younger, and had 
higher education, and were less often physically active (based on the data from the background 
surveys) compared with those who were randomized (Table 2). Blood pressure and serum cholesterol 
levels were similar in both groups at the time of earlier surveys. Slightly more women than men 
attended the screening visit but more men than women were eventually randomized. At most study 
sites, about half of the screened persons were randomized, however, in Turku 36% and Oulu 42% of 
the screened persons were randomized. As expected, based on the inclusion criteria, cognitive test 
scores were higher among those that did not fulfil the inclusion criteria. 
Table 2. Characteristics of the persons who attended the screening visit according to 
eligibility to the trial (mean (SD) or %). 
Characteristic 
Randomized 
n = 1260 
Not Randomized 
n = 1394 
p-Value 
Age at the screening visit (years) 69.2 (4.7) 68.3 (4.9) <0.001 
Sex (% men/women) 53.3/46.7% 44.8/55.2% <0.001 
Study site:    
 Helsinki (n = 389) 53.5 46.5 <0.001 
 Kuopio (n = 625) 55.2 44.8  
 Oulu (n = 240) 41.7 58.3  
 Seinäjoki (n = 326) 49.7 50.3  
 Turku (n = 656) 36.4 63.6  
 Vantaa (n = 418) 49.3 50.7  
Demographic and vascular risk factors from the earlier non-intervention survey  
Time between earlier survey and invitation (years) 13.1 (10.1) 12.0 (9.2) 0.003 
Education (years) 10.0 (3.3) 11.4 (4.0) <0.001 
Systolic blood pressure (mmHg) 141.8 (18.8) 142.2 (18.5) 0.599 
Total cholesterol (mmol/L) 5.8 (1.1) 5.8 (1.1) 0.196 
Body mass index (kg/m2) 27.6 (4.4) 27.9 (4.6) 0.062 
Physical activity at least 2 times/ week (%) 54.6 50.4 0.032 
Dementia Risk Score (points) 8.3 (1.8) 8.0 (1.6) <0.001 
Vascular risk factors and cognitive performance at the FINGER screening visit  
Systolic blood pressure (mmHg) 143.4 (18.2) 142.8 (17.7) 0.413 
Diastolic blood pressure (mmHg) 81.8 (10.1) 81.9 (10.2) 0.808 
Body mass index (kg/m2) 28.4 (6.2) 28.8 (9.4) 0.189 
Mini Mental State Examination (points) 26.7 (2.0) 28.0 (1.9) <0.001 
CERAD Word List Learning (words) 18.4 (3.2) 21.9 (3.5) <0.001 
CERAD Word Recall (words) 5.5 (1.7) 7.5 (1.8) <0.001 
CERAD Category Fluency (words) 21.6 (5.7) 23.7 (6.4) <0.001 
CERAD: Consortium to Establish a Registry for Alzheimer’s Disease. 
A majority of not randomized persons were not eligible due to high cognitive performance at the 
screening visit (n = 1097). Those who were not randomized due to other reasons (n = 297) were older 
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and had lower cognitive performance at the screening visit than the randomized participants, but their 
vascular characteristics in earlier surveys and at the screening visit did not differ (results not shown). 
3.3. Randomization into Intervention vs. Control Group 
There were no significant differences in sociodemographic, vascular, or lifestyle characteristics 
between the persons randomized into the intervention and control groups (Table 3). Overall, several 
vascular risk factors and unhealthy lifestyle factors were present. Nearly 66% of the participants 
reported history of hypertension and 67% hypercholesterolemia, and 50% had elevated systolic blood 
pressure and 54% had elevated serum total cholesterol values at the baseline visit. Approximately 30% 
of the participants were obese, and 71% were engaged in physical activity at least 2 times per week. 
Table 3. Baseline characteristics of the persons who were randomized to the trial (mean (SD) or %). 
Characteristics at Baseline n 
All 
n = 1260 
Intervention 
n = 631 
Control 
n = 629 
p-Value 
Demographic characteristics      
Age at the baseline visit (years) 1260 69.4 (4.7) 69.5 (4.7) 69.2 (4.7) 0.27 
Sex (men/women, %) 1260 53.3/46.7 54.7/45.3 52.0/48.0 0.34 
Education (years) 1244 10.0 (3.4) 10.0 (3.5) 10.0 (3.4) 0.91 
Married/ cohabiting (%) 1259 74.3 73.0 75.5 0.31 
Vascular factors      
Systolic blood pressure (mmHg) 1249 140.1 (16.2) 140.2 (16.7) 140.0 (15.7) 0.75 
Systolic blood pressure > 140 mmHg 1249 50.3 50.6 50.0 0.84 
Diastolic blood pressure (mmHg) 1249 80.3 (9.5) 80.5 (9.6) 80.1 (9.3) 0.48 
Diastolic blood pressure > 90 mmHg 1249 15.0 15.9 14.0 0.33 
Serum total cholesterol (mmol/L) 1255 5.2 (1.0) 5.2 (1.0) 5.2 (1.0) 0.93 
Serum total cholesterol > 5.0 mmol/L 1255 53.7 53.8 53.6 0.94 
Fasting plasma glucose (mmol/L) 1257 6.1 (0.9) 6.1 (0.8) 6.1 (1.0) 0.99 
Fasting plasma glucose >7.0 mmol/L 1257 10.5 10.5 10.5 0.98 
2 h oral glucose tolerance test (mmol/L) 1085 7.0 (2.2) 7.0 (2.2) 7.0 (2.2) 0.95 
2 h oral glucose tolerance test > 11.0 mmol/L 1085 5.6 5.7 5.5 0.90 
Body mass index (kg/m2) 1249 28.2 (4.7) 28.3 (4.5) 28.1 (4.9) 0.46 
Body mass index > 30 kg/m2 1249 29.9 29.8 29.9 0.98 
Waist circumference (cm) 1250 98.3 (12.6) 98.7 (12.2) 97.9 (13.1) 0.28 
Lifestyles      
Physical activity at least 2 times/ week (%) 1238 71.0 70.0 72.0 0.46 
Current smokers (%) 1214 9.4 10.5 8.3 0.17 
Alcohol drinking at least once/week (%) 1250 51.4 51.5 51.2 0.91 
Fish intake at least twice/week (%) 1250 52.3 53.2 51.4 0.54 
Daily intake of vegetables (%) 1252 61.9 61.5 62.3 0.77 
Self-reported medical conditions      
Hypertension (%) 1246 65.9 66.7 65.1 0.54 
Hypercholesterolemia (%) 1250 67.2 65.4 69.0 0.17 
Diabetes (%) 1250 13.1 13.7 12.5 0.52 
History of myocardial infarction (%) 1254 5.1 5.2 5.0 0.82 
History of stroke (%) 1251 5.4 5.3 5.6 0.79 
Other      
Dementia risk score 1260 8.3 (1.8) 8.3 (1.8) 8.3 (1.8) 0.92 
Short Physical Performance Battery score 1178 10.8 (1.5) 10.8 (1.5) 10.8 (1.5) 0.96 
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The mean MMSE score was 26.7 (SD 2.0), and it was similar in the intervention and control 
groups. There were no statistically significant differences on the individual sub-items of the main 
outcome variable mNTB between the intervention and control groups at baseline (Table 4). On average 
77% (SD 22) of the items were remembered on the CERAD word recall test (delayed recall/immediate 
recall of 3rd list). 
Table 4. Cognitive performance of the randomized participants and formation of the 
cognitive outcome modified Neuropsychological Test Battery (mean (SD)). 
Characteristics at Baseline 
 
n 
All 
n = 1260 
Intervention 
n = 631 
Control 
n = 629 
p-Value 
Memory      
WMS-R Logical Memory (immediate) 1258 11.0 (3.7) 10.9 (3.8) 11.1 (3.6) 0.37 
WMS-R Logical Memory (delayed) 1257 9.3 (3.9) 9.2 (4.0) 9.5 (3.8) 0.17 
CERAD Word List Learning 1257 18.4 (3.2) 18.3 (3.2) 18.6 (3.3) 0.08 
CERAD Word List Recall 1255 5.5 (1.7) 5.5 (1.7) 5.6 (1.7) 0.46 
WMS-R Visual Paired Associates (immediate) 1239 9.1 (3.8) 8.9 (3.8) 9.3 (3.8) 0.08 
WMS-R Visual Paired Associates (delayed) 1237 3.4 (1.8) 3.3 (1.8) 3.4 (1.8) 0.38 
Executive function      
CERAD Category Fluency 1257 21.6 (5.7) 21.3 (5.6) 21.8 (5.8) 0.13 
WMS-R Digit Span (total) 1258 11.5 (2.9) 11.5 (2.9) 11.4 (2.9) 0.64 
CST (condition C) * 1157 65.2 (40.6) 64.3 (37.2) 66.1 (43.7) 0.44 
TMT shifting score (B-A) * 1180 107.7 (65.7) 110.8 (66.9) 104.6 (64.4) 0.10 
Stroop test interference score (3-2) * 1240 34.6 (18.0) 34.8 (18.1) 34.4 (17.8) 0.69 
Processing speed      
Letter Digit Substitution Test 1253 22.0 (6.0) 21.7 (5.9) 22.2 (6.0) 0.14 
CST (condition A) * 1256 33.1 (9.5) 33.3 (8.9) 32.8 (10.0) 0.33 
Stroop test (condition 2) * 1251 29.5 (6.4) 29.6 (6.3) 29.3 (6.5) 0.55 
Mini Mental State Examination 1257 26.7 (2.0) 26.7 (2.0) 26.8 (2.0) 0.55 
* Timed task where smaller number indicates faster performance/better test result. In other tasks bigger number indicates 
better result. WMS-R: Wechsler Memory Scale-Revised; CERAD: Consortium to Establish a Registry for Alzheimer’s 
Disease; CST: Concept Shifting Test; TMT: Trail Making Test. 
3.4. Discussion 
The FINGER study is one of the first large multidomain intervention studies aiming at preventing 
cognitive impairment and dementia. Participants were recruited from earlier non-intervention 
population-based surveys in Finland, which gives unique background information about the target 
population typically not available in clinical trials. Analysing these data indicates that persons who did 
not attend the screening visit of the FINGER study were older, more often men, less educated and had 
more vascular and lifestyle related risk factors compared to those who were screened. However, 
baseline clinical characteristics of the participants indicate that several vascular risk factors and 
unhealthy lifestyle related factors were present, creating a window of opportunity for prevention. The 
intervention and control groups were similar at the beginning of the trial indicating that the 
randomization worked well. 
Our results are in line with previous epidemiological studies on dementia/AD showing that 
participants are in general younger, more educated, and healthier than non-participants [9–11]. 
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However, very little has been known about participation in prevention trials targeting lifestyle related 
risk factors among elderly persons. Because the FINGER study includes a long-term and relatively 
intensive multidomain intervention, it was expected that older persons with worse health status were 
less likely to participate. To balance the healthy volunteer bias that is often present especially in 
studies using advertisement, we used the CAIDE Dementia Risk score as one inclusion criteria.  
We used the cut-off of 6 points or more in the CAIDE risk score to select persons with some 
modifiable risk factors [15,19]. A large proportion (more than 80%) of the target-aged population met 
these criteria based on the data from the earlier population-based surveys, and only those with a very 
low risk of dementia were excluded. 
The FINGER population was defined in relation to the goals of the trial and was not intended to be 
representative of the general population. Nevertheless, the levels of several risk factors in our 
randomized participants were quite similar to those observed in the general population of the same age: 
for example in the National FINRISK study in 2012 [29], mean serum total cholesterol level in the 
Finnish population aged 65–74 years was 5.6 in women and 5.0 mmol/L in men, mean body mass 
index 28.0 and 28.3 kg/m2, and mean systolic blood pressure 146 and 144 mmHg, respectively. 
However, the proportion of persons with self-reported hypertension and hypercholesterolemia was 
higher and the proportion of those with regular physical activity was lower in our study population 
than in the general population of the same age. This is in line with the fact that the CAIDE Dementia 
Risk Score including the previously mentioned factors was used in recruiting the participants of the 
FINGER study. 
Our inclusion criteria for cognition at the screening visit were used in order to select a high-risk 
population, and to exclude both the individuals whose cognitive performance was above the mean 
level for their age and those with substantial cognitive impairment or dementia. While the main reason 
for non-eligibility was too good cognitive performance, the group of non-randomized persons was still 
heterogeneous and included also persons with too low cognitive performance, severe diseases or 
otherwise unable/willing to participate to the trial. As the CAIDE risk score emphasizes vascular risk 
factors and the cognitive inclusion criteria is memory-related, in theory our study population is at risk 
of both AD type and vascular cognitive impairment. The mean cognitive performance of our study 
population was less than 0.5 SD below the average level of a cognitively normal Finnish population. 
The neuropsychological test battery that was used in the FINGER study includes a set of widely used 
standard tests, and it is a modified version of test battery that was previously shown to be sensitive to 
cognitive changes in persons with mild AD [23]. We added standard tests measuring attention and 
executive functions to the original test battery, in order to better capture also changes typical in 
vascular cognitive impairment. 
In order to have high external validity, i.e., that our results would be as generalizable as possible, 
we kept the exclusion criteria to the minimum and used six study areas that provided good 
geographical coverage within Finland and comprised both urban and rural areas. The participants were 
invited from earlier population-based surveys that had very good participation rates and therefore can 
be considered well representative of the Finnish population. Although we have important information 
of the characteristics of the screening visit non-attendees, we do not know why they chose not to 
attend. Both the nature of the trial and characteristics (such as age or health status) of the target 
population may have played a role. It remains a task for the future to identify if there is something we 
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could do to facilitate participation in future trials and/or when implementing preventive strategies into 
practice. The differences between the screening visit attendees and non-attendees will not compromise 
the expected results of our trial, but they are important to identify in order to understand to what extent 
our results may be generalizable to the population at-large. We hypothesize that the persons with more 
risk factors would benefit more from the intervention, so given the fact that the study participants  
had somewhat less risk factors present may underestimate the effect of the intervention in the whole 
target population. 
The FINGER study is using an existing infrastructure and a research framework built for 
cardiovascular risk factor monitoring to recruit a population that would benefit most from the 
intervention. Detailed information on earlier lifestyle and vascular factors is available, and differences 
in these variables can be taken into account in the analyses, which is usually not possible in 
randomized controlled trials. An extended follow-up of the cohort after the end of the 2 year 
intervention will provide much needed information on the long-term effects of the 2-year intervention, 
especially on the incidence of dementia/AD. We will utilize the exceptional opportunities available in 
Finland, including structured and detailed health registers of high quality, to ensure a complete  
long-term follow-up on a wide range of outcomes also for the persons who did not participate in the 
screening or the actual trial, were not included or dropped out during the study. 
4. Conclusions 
Vascular risk factors were more common among those who did not attend the FINGER study 
screening visit than among those who attended. Nevertheless, as expected from the inclusion criteria 
the participants had several modifiable risk factors for dementia and cognitive impairment at baseline 
indicating a window of opportunity for the intervention. The random allocation of participants to the 
intervention and control groups was successful. The FINGER study is expected to provide important 
novel information on the effect of lifestyle intervention to prevent cognitive impairment among at risk 
persons selected from the general population. 
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